Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Molina-Cerrillo

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Clinical Genitourinary Cancer|December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 StudyFernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Investigational New Drugs|May 4, 2026
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsAlejandro Falcón, Gregory M Cote, Javier Molina-Cerrillo, et al.
Urologic Oncology|May 15, 2026
Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective studyPatricia Rioja, Carolina Passarella, Martín Angel, et al.
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914)Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, et al.
Targeted Oncology|August 10, 2022
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination TherapiesMatteo Santoni, Javier Molina-Cerrillo, Zin W Myint, et al.
Clinical & Experimental Metastasis|June 8, 2024
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 projectAlessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, et al.
European Urology Oncology|April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 StudyFrancesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 studyGiandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Pageof 10